|
[posting]62509154[/posting]https://seekingalpha.com/article/4317789-cassava-sciences-an… Cassava’s Drug Discovery "SAVA has two products in its pipeline for which it owns proprietary, worldwide rights, without royalty or milestone obligations. PTI-125 is an oral, small molecule drug that is now in the middle of a Phase 2(B) study, with results expected by mid-2020. It receives long-term scientific & financial support from the National Institute of Health (NIH) PTI-125Dx is an Alzheimer’s detection (diagnostic) system. It is currently undergoing clinical testing. Both products will enter the pivotal (or clinical) trial phase in 2021, and after positive results will be ready to be marketed. Currently, Alzheimer’s can be definitively diagnosed only after death. Therefore, if the PT-125Dx’s clinical tests are successful, along with a successful PT-125, this will imply bumper prospects for the company. For SAVA, its current results do not matter. What matters is the success of their trials. The progress of whatever is happening is known only to the insiders." "Between 26 Sep 2019 and 31 Dec 2019, SAVA insiders bought over 700,000 shares between $1.02 and $5.53. The last purchase was by Barbier Remi (CEO) at $5.53. The largest purchase of 423,000 shares was made by a director at $2.20." |
|
| aus der Diskussion: | Pain! Wann gehts wieder nach Norden? |
| Autor (Datum des Eintrages): | clearasil (28.01.20 15:03:07) |
| Beitrag: | 31 von 34 (ID:62509196) |
| Alle Angaben ohne Gewähr © wallstreetONLINE | |